184 related articles for article (PubMed ID: 35941390)
1. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
[TBL] [Abstract][Full Text] [Related]
3. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
[TBL] [Abstract][Full Text] [Related]
4. t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities.
Baldazzi C; Luatti S; Marzocchi G; Grassi A; Cavo M; Testoni N
Cancer Genet; 2022 Apr; 262-263():35-39. PubMed ID: 34979355
[TBL] [Abstract][Full Text] [Related]
5. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
6. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
[TBL] [Abstract][Full Text] [Related]
7.
Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
[TBL] [Abstract][Full Text] [Related]
8. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.
Qin H; Malek S; Cowell JK; Ren M
Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
[TBL] [Abstract][Full Text] [Related]
9. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.
Sandahl JD; Coenen EA; Forestier E; Harbott J; Johansson B; Kerndrup G; Adachi S; Auvrignon A; Beverloo HB; Cayuela JM; Chilton L; Fornerod M; de Haas V; Harrison CJ; Inaba H; Kaspers GJ; Liang DC; Locatelli F; Masetti R; Perot C; Raimondi SC; Reinhardt K; Tomizawa D; von Neuhoff N; Zecca M; Zwaan CM; van den Heuvel-Eibrink MM; Hasle H
Haematologica; 2014 May; 99(5):865-72. PubMed ID: 24441146
[TBL] [Abstract][Full Text] [Related]
10. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.
Ommen HB; Touzart A; MacIntyre E; Kern W; Haferlach T; Haferlach C; Tobal K; Hokland P; Schnittger S
Eur J Haematol; 2015 Nov; 95(5):436-41. PubMed ID: 25605311
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
Díaz-Beyá M; Labopin M; Maertens J; Aljurf M; Passweg J; Dietrich B; Schouten H; Socié G; Schaap N; Schwerdtfeger R; Volin L; Michallet M; Polge E; Sierra J; Mohty M; Esteve J; Nagler A;
Br J Haematol; 2020 Jun; 189(5):920-925. PubMed ID: 32020596
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Gao MG; Fu Q; Qin YZ; Chang YJ; Wang Y; Yan CH; Xu LP; Zhang XH; Huang XJ; Zhao XS
Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):868-874. PubMed ID: 34551474
[No Abstract] [Full Text] [Related]
13. Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.
Ikeda D; Chi S; Uchiyama S; Nakamura H; Guo YM; Yamauchi N; Yuda J; Minami Y
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682627
[TBL] [Abstract][Full Text] [Related]
14. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
Zimmermannova O; Doktorova E; Stuchly J; Kanderova V; Kuzilkova D; Strnad H; Starkova J; Alberich-Jorda M; Falkenburg JHF; Trka J; Petrak J; Zuna J; Zaliova M
Oncogene; 2017 Oct; 36(43):5985-5994. PubMed ID: 28650474
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
Campregher PV; Halley NDS; Vieira GA; Fernandes JF; Velloso EDRP; Ali S; Mughal T; Miller V; Mangueira CLP; Odone V; Hamerschlak N
Leuk Lymphoma; 2017 Dec; 58(12):2969-2972. PubMed ID: 28509585
[No Abstract] [Full Text] [Related]
16. Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
Zhang X; Zhang X
Ann Palliat Med; 2021 Apr; 10(4):4955-4958. PubMed ID: 33832283
[TBL] [Abstract][Full Text] [Related]
17. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia.
La Starza R; Trubia M; Testoni N; Ottaviani E; Belloni E; Crescenzi B; Martelli M; Flandrin G; Pelicci PG; Mecucci C
Haematologica; 2002 Aug; 87(8):789-94. PubMed ID: 12161353
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
Xue S; Sun HP; Huang XB; Chen X; Wang T; Ma W; Tian Y; Pan ZL; Li LH; Zhang L; Liu HX; Cao XY
Int J Hematol; 2024 May; 119(5):564-572. PubMed ID: 38441775
[TBL] [Abstract][Full Text] [Related]
19. The DEK oncoprotein and its emerging roles in gene regulation.
Sandén C; Gullberg U
Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544
[TBL] [Abstract][Full Text] [Related]
20. Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.
Piredda ML; Catalano G; Ciardi C; Divona M; Cicconi L; Panetta P; Curzi P; Garza E; Martínez-Losada C; Postorino M; Lo-Coco F; Noguera NI
Ann Hematol; 2017 Jan; 96(1):155-157. PubMed ID: 27734129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
